Study wrapper · #1058
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Editor's note
A Markov cost-effectiveness model comparing semaglutide 2.4 mg and resmetirom against standard of care for MASH from a US payer perspective. It is an economic simulation rather than new clinical evidence, drawing on prior trials such as ESSENCE and MAESTRO-NASH, so the findings reflect modeling assumptions rather than head-to-head outcomes. Readers can read the results as a health-economics argument for semaglutide's value, not a clinical efficacy comparison.
Plain-language abstract
This US cost-effectiveness modeling study estimated that semaglutide 2.4 mg offered more quality-adjusted life years at a far lower incremental cost per QALY than resmetirom for non-cirrhotic MASH with moderate to advanced fibrosis. The authors concluded semaglutide was economically favorable from a payer perspective across the thresholds tested.